Conference Call Summary, page-404

I say, separate the 2: The Adult and the Children trials. go full steam ahead with the Adult trials and publish the findings and let the academic/market/FDA judge, and provide more sterilised environment for Children trials, which includes a dedicated person from RAP conducting those trials, (the cost to the company and to Shareholders from the SP collapse justify the cost of the dedicated person).
In any case at the end of the day, I believe you are going to have 2 separate cough algorithms: 1 for Adult and 1 for Children, and perhaps 2 separate versions of the ResApp.

It is a set back which should've been anticipated, but I still believe in RAP, and believe that the algorithm which worked brilliantly for Adults will work as good for the Children.
It is a matter of environmental control, and smarter administration of the trials.